P3 Health Partners Inc

P3 Health Partners Inc(PIII)股票分析

$4.010

+0.199 (+4.97%)收盤時

Loading chart…
最高
4.100
開盤
3.970
成交量加權均價
4.03
成交量
7.11K
市值
91.20M
最低
3.970
成交金額
28.62K
企業價值/稅息折舊攤銷前利潤(TTM)
3.35

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

AI 分析 of P3 Health Partners Inc (PIII)

買進

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

估值指標

P3 Health Partners Inc(PIII)目前預期本益比為 0.00,5 年平均預期本益比為 -3.14。

預期本益比

合理
5 年均值 P/E
-3.14
目前P/E
0.00
高估
3.05
低估
-9.34

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-2.05
目前EV/EBITDA
3.35
高估
90.93
低估
-95.03

預期股價營收比

嚴重高估
5 年均值 P/S
0.13
目前P/S
0.46
高估
0.24
低估
0.02

Alphio AI 對 PIII 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%PIII

$8.18

情境價格

基

基準

基準 · 50%PIII

$7.60

情境價格

悲

悲觀

悲觀 · 25%PIII

$6.61

情境價格

事件時間軸

2026-10-15 (ET)

06:30:00

Selling Stockholders Plan to Sell 15.64M Shares of Class A Common Stock

2026-10-12 (ET)

09:30:00

P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer

2026-08-10 (ET)

16:30:00

Sees FY26 Adjusted EBITDA of $80M-$110M

16:30:00

P3 Reports Q2 Revenue of $386.38M, Beating Expectations

2026-05-19 (ET)

10:00:00

P3 Health Partners Inc Trading Resumes

資訊

PIII 常見問題 —— 由 Alphio AI 解答

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易